

ATMP Clinical Trials

Therapy Name and vector, if applicable (Developer)	Therapy Type (Indication)	Trial Phase (Status)	Clinical Trial Database number, EudraCT/EU CT Protocol code number / Title of the trial (Start Year)	Disease Area	Cell Type	Gene Therapy	Autologous / Allogeneic	Site(s) in Sweden
CTL019 / Kymriah, lentiviral vector (Novartis)	GTMP (Paediatric and young adult patients with B-cell acute lymphoblastic leukemia (B ALL))	II (In follow-up)	NCT03876769, 2023-508081-15-00 CTL019G2201 / CASSIOPEIA (2021)	Paediatric oncology	T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg
Ciltacabtagene Autoleucel / ciltacel, lentiviral vector (Janssen-Cilag)	GTMP (Multiple myeloma)	III (In follow-up)	NCT04923893, 2021-001242-35 MMY3004 / CARTITUDE-5 (2022)	Oncology	T cells	Yes, ex vivo	Autologous	Linköping University Hospital, Linköping Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund

Posoleucel (AlloVir)	sCTMP (Adenovirus Infection after allogenic transplantation)	III (Completed)	NCT05179057, 2021-003450-22 (2022) P-105-303	Paediatrics - adenovirus infection after allogenic transplantation	Multi-virus specific T cell therapy; Virus infected previously in hematopoietic cell transplanted patients	No	Allogeneic	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund
SRP-9001, Delandistrogene moxeparvovec, rAAVrh74 containing human micro-dystrophin gene (Sarepta Therapeutics)	GTMP (Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy)	III (Recruiting)	NCT05881408, 2020-002372-13 (2022) SRP-9001-303 / ENVISION	Paediatric neurology	N/A	Yes, in vivo	N/A	Sahlgrenska University Hospital, Göteborg Karolinska University Hospital, Stockholm
BNT113 (BioNTech SE)	GTMP (Unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD- L1)	II (Completed)	NCT04534205, 2020-001400-41 (2022) BNT113-01 / AHEAD-MERIT	Oncology	N/A	Yes, in vivo	N/A	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund

Autologous Tumor Infiltrating Lymphocytes (Göteborg University)	sCTMP (Patients with melanoma and liver metastases)	I (In follow-up)	NCT04812470, 2020-006126-31 (2023) 01-2020-06916 / HAITILS	Oncology - melanoma	Tumor Infiltrating Lymphocytes (TILs)	No	Autologous	Sahlgrenska University Hospital, Göteborg
mRNA-4157 / V940 (MSD)	GTMP (Malignant melanoma)	III (In follow-up)	NCT05933577, 2023-503652-27- 00 001-00 / INTerpath-001 (2023)	Malignant melanoma	N/A	Yes, in vivo	Autologous	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund
XSTEM-VLU (Xintela)	sCTMP (Venous leg ulcers)	I/II (Completed)	NCT05549609, 2022-000492-39 XIN-XSTEM-201 (2023)	Dermatology (chronic wounds)	Integrin α 10 β 1- selected mesenchymal stem cells	No	Allogeneic	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund
Ciltacabtagene Autoleucel / cilta-cel, lentiviral vector (European Myeloma Network)	GTMP (Multiple myeloma)	III (In follow-up)	NCT05257083, 2021-003284-10/ 2023-507632-20- 00 EMN28/68284528 MMY3005 / CARTITUDE-6 (2023)	Oncology	T cells	Yes, ex vivo	Autologous	Linköping University Hospital, Linköping Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund. Uppsala University Hospital, Uppsala

Lifileucel / LN-144 (Iovance Biotherapeutics)	sCTMP (untreated, unresectable or metastatic melanoma)	III (Recruiting)	NCT05727904, 2022-503140-41-00 IOV-MEL-301 / TILVANCE-301 (2024)	Oncology	Tumor Infiltrating Lymphocytes (TILs)	No	Autologous	Sahlgrenska University Hospital, Göteborg
Allo-APZ2-CVU (RHEACELL)	sCTMP (Therapy-resistant non-healing chronic venous ulcers (CVU))	III (In follow-up)	NCT06489028, 2024-512720-11 allo-APZ2-CVU-III (2025)	Skin and subcutaneous tissue disorders	Mesenchymal Stromal Cells	No	Allogeneic	Academic primary care center, Uppsala Sahlgrenska University Hospital, Göteborg
Autogene cevumeran (Genentech, Inc.)	GTMP (Pancreatic adenocarcinoma)	II (Recruiting)	NCT05968326, 2022-502404-73-00 GO44479 / IMCODE003 (2025)	Pancreatic adenocarcinoma	N/A	Yes, in vivo	Autologous	Sahlgrenska University Hospital, Göteborg
Autogene cevumeran (Roche)	GTMP (urothelial carcinoma)	II (Recruiting)	NCT06534983, 2023-509023-40-00 BO45230 / IMCODE004 (2025)	Urothelial carcinoma	N/A	Yes, in vivo	Autologous	Sahlgrenska University Hospital, Göteborg
N-TEC (University Hospital Basel)	cATMP (patellofemoral osteoarthritis)	II (Recruiting)	NCT06576583, 2024-513683-25-00 ENCANTO	Patellofemoral osteoarthritis	Chondrocytes	No	Autologous	Sahlgrenska University Hospital, Göteborg

			(2026)					
Arlocabtagene Autoleucel / Arlo-cel, lentiviral vector (Bristol Myers Squibb)	GTMP (Multiple Myeloma)	III (Recruiting)	NCT06615479, 2024-515279-37-00 CA088-1007 / QUINTESSENTIAL-2 (2026)	Oncology	T cells	Yes, ex vivo	Autologous	Sahlgrenska University Hospital, Göteborg